MAIA Biotechnology, Inc. MAIA
Set alert
As of Nov 3, 10:13 AM ET
- YTD
- -26.14%
- 1 year
- -2.59%
- Open
- 1.08
- Prev close
- 1.10
- Mkt cap
- 70.23M
- Vol
- 18.02K
- Avg vol
- 453.41K
- EPS
- -0.62
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.10
- High
- 1.14
- Forward P/E
- -1.25
- Beta
- 0.34
- Short ratio
- 10.99
- Inst. own
- 7.51%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.41
- 200-d avg
- 2.83
- 1y target
- 12.63
5D chart
Signals (63)
| Name | Time | Ago |
|---|---|---|
| MACD: Buy Signal | Nov 2, 11:45 AM | 22 hours ago |
| MACD: Sell Signal | Nov 2, 10:45 AM | 23 hours ago |
| SMA: Bullish | Oct 30, 3:10 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 3:10 PM | 3 days ago |
| RSI: Oversold | Oct 30, 3:05 PM | 3 days ago |
| RSI: Oversold | Oct 30, 2:15 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 1:35 PM | 3 days ago |
| RSI: Oversold | Oct 30, 1:35 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 12:05 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 11:35 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:20 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 11:00 AM | 4 days ago |
| MACD: Sell Signal | Oct 30, 10:50 AM | 4 days ago |
| MACD: Buy Signal | Oct 30, 10:45 AM | 4 days ago |
| RSI: Oversold | Oct 30, 10:10 AM | 4 days ago |
| RSI: Oversold | Oct 30, 9:40 AM | 4 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 4 days ago |
| RSI: Oversold | Oct 30, 9:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 3:50 PM | 4 days ago |
Newest 20 of 63.
News
3 weeks ago benzinga.com
Alpha Buying: 4 Biotech Stocks Insiders Are Betting On
I can sit through a biotech presentation and come away convinced that the company has discovered the answer to half the problems in modern medicine. The slides look terrific. The market opportunity…
-
3 weeks ago benzinga.com
MAIA Biotechnology Completes Enrollment Of Patients For Part C Of Phase 2 Study Of Ateganosine Sequenced With CPI Cemiplimab To Treat Non-Small Cell Lung Cancer
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has reached…
-
1 month ago benzinga.com
MAIA Biotechnology Files Resale Prospectus For 751,879 Shares Issued Under Clinical Trial Funding Agreement
PRELIMINARY PROSPECTUSSubject to completion, dated September 25, 2026 751,879 Shares of Common Stock Pursuant to this prospectus, the selling stockholder identified herein (the "Selling Stockholder")…
-
1 month ago benzinga.com
MAIA Biotechnology Receives Regulatory Approval By The Spanish Agency For Medicines And Medical Devices And Portugal’s National Authority Of Medicines And Health Products To Begin Screening Patients For Its Ongoing Pivotal Phase 3 THIO-104 Clinical Trial In Non-Small Cell Lung Cancer
THIO-104 advances toward key 2027 interim survival analysisCHICAGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical
-
1 month ago benzinga.com
MAIA Biotechnology Says First US Patient Dosed In Phase 2 THIO-101 Trial Expansion Evaluating Telomere-Targeting Lead Candidate, Ateganosine, In Third-Line Non-Small Cell Lung Cancer
Milestone follows FDA clearance of MAIA’s amended investigational new drug (IND) submission highlighting improved manufacturing capabilities and efficiencies U.S. expansion is funded by a $2.3…
-
1 month ago benzinga.com
MAIA Biotechnology CEO Vlad Vitoc Buys 73K Shares At An Average Price Of $1.37 Per Share; Board Member Ramiro Guerrero Buys 185,078 Shares At An Average Price Of $1.36 Per Share
Board member Ramiro Guerrero, JD, LL.M. has increased his ownership stake in the Company through open market purchases totaling approximately $252,284. A total of 185,078 shares of MAIA common stock…
2 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Intelligent Bio Solutions (NASDAQ:INBS) stock moved upwards by 8.2% to $2.63 during Tuesday's after-market session. The company's market cap stands at $7.2 million. Jaguar Health…
-
2 months ago benzinga.com
MAIA Biotechnology Q2 EPS $(0.13) Misses $(0.11) Estimate
MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 27.78 percent increase over losses of…
-
3 months ago benzinga.com
MAIA Biotechnology Reports 90.5% Disease Control Rate In Phase 2 THIO-101 Clinical Trial Of Ateganosine For Advanced Non-Small Cell Lung Cancer
90.5% interim disease control rate (DCR) observed with combination therapyInitial Part C efficacy observations align with previously reported THIO-101 clinical activity despite a more heavily…
-
4 months ago benzinga.com
MAIA Biotechnology Completes Global Enrollment In Part C Of Its Phase 2 THIO-101 Expansion Study Of Ateganosine To Treat Advanced Non-Small Cell Lung Cancer
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has…
-
5 months ago benzinga.com
MAIA Biotechnology Provides A Patient Enrollment Update For Its Ongoing Pivotal Phase 3 Trial, THIO-104; 29 Patients Have Been Dosed Among 34 Activated Trial Sites In 6 Foreign Countries
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today provided a patient enrollment…
-
5 months ago benzinga.com
MAIA Biotechnology Receives FDA IND Clearance To Expand THIO-101 Phase 2 NSCLC Trial In U.S. With Ateganosine; Updates Manufacturing Protocols Supporting Potential Accelerated Approval Pathway
Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Approval filing with FDAFDA-cleared IND updates detail latest efficacy data and enriched…
-
5 months ago benzinga.com
MAIA Biotechnology Insiders Founder/CEO Vlad Vitoc, M.D. And Director Stan V. Smith, Ph.D. Increase Ownership Position Through Open Market Purchases Of ~147,700 Shares Worth ~$201K
Approximately 72,700 shares of MAIA common stock were purchased by Dr. Vitoc on June 6, 2026, at an average common stock price of $1.3877. Approximately 75,000 shares of MAIA common stock were…
-
5 months ago benzinga.com
MAIA Biotechnology Announces That It Delivered A Poster Presentation Featuring The Methodology And Study Design For Its Pivotal Phase 3 Clinical Trial On May 31 At The 2026 Annual Meeting Of The American Society Of Clinical Oncology
THIO-104 evaluates the efficacy of MAIA's telomere targeting agent, ateganosine, administered in sequence with a checkpoint inhibitor (CPI) in third-line non-small cell lung cancer (NSCLC) patients…
5 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
5 months ago benzinga.com
MAIA Biotechnology Q1 EPS $(0.14) Beats $(0.18) Estimate
MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.18) by 22.22 percent. This is a 12.5 percent increase over losses of…
-
6 months ago benzinga.com
MAIA Biotechnology Activates First Clinical Facility In U.S. In Its Phase 2 THIO-101 Expansion Study To Treat Non-Small Cell Lung Cancer
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has…
-
7 months ago benzinga.com
MAIA Biotechnology Reports Over 2-Year Survival In Phase 2 THIO-101 NSCLC Trial;
Potential breakthrough therapeutic targets $50B+ global immunotherapy market1CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage…
-
7 months ago benzinga.com
MAIA Biotechnology Q4 EPS $(0.08) Beats $(0.13) Estimate
MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.13) by 38.46 percent. This is a 33.33 percent increase over losses of…
-
8 months ago benzinga.com
Is the Market Bullish or Bearish on MAIA Biotechnology Inc?
Is the Market Bullish or Bearish on MAIA Biotechnology Inc?
8 months ago benzinga.com
Crude Oil Surges Over 6%; Target Profit Tops Views
US stocks down amid Iran-US conflict. Tehran closed Strait of Hormuz & warned of firing on vessels. Dow down 2.45%, NASDAQ down 2.62%, S&P 500 down 2.34%.
8 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
8 months ago benzinga.com
Dow Dips 900 Points; Best Buy Posts Upbeat Earnings
U.S. stocks traded lower this morning, with the Dow Jones index falling more than 900 points on Tuesday amid the ongoing Iran-U.S. conflict. Iranian state media reported that Tehran has closed the…
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
8 months ago benzinga.com
Why Ouster Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Shares of Ouster Inc (NASDAQ:OUST) rose sharply in pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued first-quar
-
8 months ago benzinga.com
MAIA Biotechnology Reveals Proposed Underwritten Public Offering of Common Stock And Pre-Funded Warrants; No Size Disclosed
MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has commenced an…
-
8 months ago benzinga.com
MAIA Biotechnology Highlights Phase 3 Momentum And FDA Fast Track For Ateganosine In Third-Line NSCLC
Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical success for interim and full analysisFDA Fast Track designation offers clear pathway for ateganosine as…
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
9 months ago benzinga.com
MAIA Biotechnology Announces Milestones And Growth Catalysts For 2026; Initial Measures Of Efficacy From Phase 3 Study, Conclusion Of Part C Of Phase 2 Study, Engage In Regulatory Interactions With The FDA, Clinical Development Of Second-generation Molecules To Start In Phase 1 Trials
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today provided a corporate update…
-
10 months ago benzinga.com
MAIA Biotechnology Announces $1.51M Private Placement Of 1.23M At A Price Of $1.224/Share With Warrants Exercisable At A Price Of $1.36/Share
MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into…
-
10 months ago benzinga.com
MAIA Biotechnology Doses First Patient In Phase 3 Trial Of Ategenosine Plus Checkpoint Inhibitor For Advanced NSCLC
Key milestone achieved as Company advances clinical program to full approval trial of ateganosine sequenced with a checkpoint inhibitor in comparison to chemotherapyCHICAGO, Dec. 11, 2025 (GLOBE…
-
11 months ago benzinga.com
MAIA Biotechnology Makes Open-Market Purchases: CEO Buys 94,300 Shares At An Average Price Of $1.08/Share; Board Members Acquire 88,145 Shares At An Average Price Of $1.04/Share, Totaling 182,445 Shares Combined
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the CEO and…
-
11 months ago benzinga.com
MAIA Biotechnology Highlights Phase 2 THIO‑101 Expansion And Phase 3 THIO‑104 Trials Of Telomere Targeting Agent Ateganosine For NSCLC At SITC 2025; FDA Grants Fast Track Designation
Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countriesPosters for Phase 2 and Phase 3 clinical trials availableCHICAGO , Nov. 21, 2025 (GLOBE…
-
1 year ago benzinga.com
MAIA Biotechnology Reports Efficacy Of Ateganosine In High-Risk Non-Small Cell Lung Cancer At ESMO 2025
Outstanding measure of efficacy relative to high-risk cancers with limited treatment options CHICAGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a…
-
1 year ago benzinga.com
MAIA Biotechnology Authorizes Up To 90% Of Liquid Assets In Bitcoin, Ethereum, And USD Coin For New Digital Treasury Strategy
MAIA's Board of Directors authorizes holdings of up to 90% of the Company's liquid assets in cryptocurrencies (BTC), Ethereum (ETH), and USD Coin (USDC)CHICAGO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- MAIA…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
1 year ago benzinga.com
MAIA Biotechnology Receives $2.3M NIH Grant To Expand THIO-101 Phase 2 Trial For Advanced Lung Cancer In U.S.
THIO-101 Phase 2 trial to enroll patients in the U.S. as part of the expansion of the study in third-line treatment for advanced non-small cell lung cancer (NSCLC)CHICAGO, Sept. 24, 2025 (GLOBE…
-
1 year ago benzinga.com
MAIA Biotechnology Highlights Efficacy Data From Phase 2 Clinical Trial, THIO-101, Evaluating Ateganosine Sequenced With Immune CPI Cemiplimab In Patients With Advanced NSCLC
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today highlighted positive efficacy…
-
1 year ago benzinga.com
MAIA Biotechnology To Present Phase 2 THIO + Cemiplimab Data In ICI-Resistant aNSCLC At IASLC WCLC 2025; Poster Highlights PFS Improvement
Poster details durability and efficacy of ateganosine (THIO) treatment in non-small cell lung cancer (NSCLC)CHICAGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA",…
-
1 year ago benzinga.com
MAIA Biotechnology's Phase 2 THIO-101 Trial Developments Published In Cells Journal
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that a manuscript…
-
1 year ago benzinga.com
MAIA Biotechnology Q2 EPS $(0.18) Beats $(0.24) Estimate
MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.24) by 25 percent. This is a 55 percent increase over losses of $(0.40)…
-
1 year ago benzinga.com
MAIA Biotechnology Announces FDA Fast Track For First-in-Class Telomere-Targeting Drug In NSCLC; Latest Data In Pivotal Phase 2 THIO-101 Clinical Trial Shows Median Overall Survival Of 17.8 Months
Potential first-to-market small molecule telomere targeting agent targets a $34 billion NSCLC treatment marketLatest data in pivotal Phase 2 THIO-101 clinical trial shows median overall survival of…
-
1 year ago benzinga.com
MAIA Biotechnology Doses First Patient In Taiwan In Expansion Phase Of THIO-101 Phase 2 Trial For Advanced Non-Small Cell Lung Cancer
MAIA Biotechnology, Inc. (NYSE:MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced dosing of the first patient in Taiwan in…
-
1 year ago benzinga.com
MAIA Biotechnology To Present Data Highlighting Cancer Telomere-Targeting Agent And Next-Generation Treatments, At FEBS 2025
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced two upcoming poster…
-
1 year ago benzinga.com
MAIA Biotechnology Enters Into Clinical Master Supply Agreement With Roche For Future Studies Investigating Combination Of MAIA's THIO, Sequenced With Roche's CPI, Atezolizumab For Cancer Treatments
Agreement to support future studies investigating the combination of ateganosine and atezolizumab for safe and effective cancer treatmentsMAIA Biotechnology, Inc. (NYSE:MAIA), a clinical-stage…
1 year ago benzinga.com
MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients
MAIA posts 17.8-month median survival in NSCLC trial, nearly tripling standard care; long-term response seen in a chemo- and immunotherapy-resistant group.
-
1 year ago benzinga.com
MAIA Biotechnology Says New Partial Response Identified In Patient After 20 Months Of Treatment In Phase 2 THIO-101 Clinical Trial Evaluating Ateganosine, Sequenced With Regeneron's Immune CPI Libtayo In NSCLC Patients
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced a new partial…
-
1 year ago benzinga.com
MAIA Biotechnology Reports Updated Phase 2 THIO-101 Trial Data Showing Median Overall Survival Of 17.8 Months With Ateganosine Plus Cemiplimab In Heavily Pre-Treated NSCLC Patients
Median overall survival (OS) from ateganosine (THIO) treatment extends to 17.8 months in latest dataMAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical…
-
1 year ago benzinga.com
MAIA Biotechnology Announces Private Placement of 446,332 Shares At $1.50/Shr
MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into…